By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Pharmaceutical Technology on MSN
Pfizer and Novavax ink $530m vaccine delivery licensing deal
Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...
Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...
Recent health sector developments highlight Moderna and Merck's promising skin cancer vaccine trial alongside China's declining birthrate, and significant business moves from pharmaceuticals giants ...
Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...
Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results